Abstract
Introduction Diagnosing lower respiratory infections (LRIs) using conventional diagnostic methods (CDMs) presents limitations in detecting suspected pathogens. This study compares the latest CDMs with shotgun metagenomic sequencing (SMS) for bronchoalveolar lavage (BAL) fluid. The primary objective is to enhance pathogen detection using SMS.
Materials and Methods A total of 16 BAL fluid samples from patients with pneumonia with positive results in various CDMs—bacterial/fungal cultures, real-time PCR for Mycobacterium tuberculosis, cytomegalovirus, or the BioFire® FilmArray Pneumonia Panel—were included. Samples were subjected to 10 Gb SMS on the NovaSeq 6000 (Illumina) and were aligned against the NCBI RefSeq database. For eukaryotic reads, an additional matching process was performed using the internal transcribed spacer (ITS) region of fungi. Antibiotic resistance genes (ARGs) were annotated using the Comprehensive Antibiotic Resistance Database model. To identify significant pathogens, thresholds for the relative abundance of SMS reads were applied to evaluate the concordance between CDM- and SMS-detected microbes.
Results The proportion of microbial reads ranged from 0.00002–0.04971% per sample. SMS detected corresponding bacterial reads (2–23,869) with relative abundance between 0.02% and 87.5%. Eukaryotic reads varied from 0 to 32, with no fungal alignment at the genus level. Candida species were identified in four samples using ITS. No viral reads were detected. In 10 out of 16 cases (63%), SMS detected pathogens above the threshold by SMS. When subdominant taxa were included, SMS detected pathogens in 11 out of 16 cases (69%). ARGs meeting perfect criteria via the Resistance Gene Identifier were observed in two cases.
Conclusion This study represents the first comparison of SMS and CDMs, including the FilmArray Pneumonia Panel, in the context of LRI diagnostics. SMS may serve as a valuable supplementary tool for LRI diagnosis. Further research is necessary to improve sensitivity and cost-effectiveness.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this study was obtained from the Institutional Review Board of Kyung Hee University Medical Center (no. 2023-05-076) on June 1, 2023. The approved collection period for archived residual samples extended until February 29, 2024. As only archived samples were used and all data were fully anonymized prior to analysis, the requirement for informed consent was waived by the IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
The raw sequencing data were submitted to the NCBI Sequence Read Archive (SRA) database (accession number PRJNA-1036216).
